Alpharmaxim logo in white

Access a revolutionary new report
addressing complex barriers to
treatment change in Parkinson’s

Access a revolutionary new report addressing complex barriers to treatment change in Parkinson’s.

Parkinson’s remains one of the greatest challenges in medicine. Most therapies only treat symptoms. Many new entrants have not reached their expected potential. In such a market, entry is difficult. The need for effective treatment is great, yet the 139 products in active clinical trials1 must overcome complex barriers to adoption.

PRE-ORDER your report before 10 July 2024 and receive a 20% discount (non-discount price £20,000)

Click REGISTER INTEREST to stay updated on the report's availability or request a free summary

PRE-ORDER REPORT
Register Interest

Access a revolutionary new report addressing complex barriers to treatment change in Parkinson’s

Parkinson’s remains one of the greatest challenges in medicine. Most therapies only treat symptoms. Many new entrants have not reached their expected potential. In such a market, entry is difficult. The need for effective treatment is great, yet the 139 products in active clinical trials1 must overcome complex barriers to adoption.

PRE-ORDER your report before 10 July 2024 and receive a 20% discount
(non-discount price £20,000)

Click REGISTER INTEREST to stay updated on the report's availability or request a free summary

PRE-ORDER REPORT
Register Interest

This groundbreaking report will equip you to understand and address barriers to changing prescribing behaviours in Parkinson’s. Beyond identifying challenges, it proposes potential solutions using the unique, validated Healthcare Behaviour Insights Tool (H-BIT) methodology developed by Alpharmaxim (experts in behavioural science-driven communications for the healthcare sector) and Aston University, UK.

Equipped with the right information, you can radically change the way you plan and execute communications, get the uptake you want and reach patients in need of new options for Parkinson’s treatment.

PRE-ORDER REPORT
Register Interest

How will the report support your work in Parkinson’s?

By harnessing the insights of the report, your communications have a greater chance of driving behaviour change and adoption of product, whether you work in Marketing, Medical Affairs, Strategic Planning, Market Access or Clinical Development.

  • Build launch plans to better differentiate your product
  • Understand market changes and be ahead of the curve
  • Understand barriers to change – and how to overcome them
  • Address key issues in the right ways using scientifically validated tools
  • Inform data collection requirements for trial designs
  • Generate a competitive advantage
  • Appreciate and address clinician behaviours in the field
  • Develop greater understanding of how to positively change behaviour
  • Deliver measurable campaign effectiveness that demonstrates real ROI

What you’ll get from the report

The H-BIT report will provide valuable detail on the drivers of behaviour that determine physicians’ decision-making, specifically focusing on their capability, opportunity and motivation to change their current behaviour.

Our research shows that when we consider an approach for Parkinson’s, directing communications solely at neurologists will not be effective. Though they are critical in prescribing, much of the support we can give to neurologists may be addressed through changing the prescribing environment – looking again at the provision of clear treatment guidelines and patient journeys, as well as better facilitating the role of non-specialist HCPs.

If these issues are addressed through the behavioural interventions covered in the report, it’s likely that neurologists will have increased capability and motivation to change prescribing patterns, and so the adoption of new therapies may be accelerated.

Many neurologists are slow to adopt new treatments for PD, and the introduction of new disease-modifying treatments will likely slow adoption further. Our report highlights several behavioural components that are responsible. Addressing these underlying challenges with focused intervention will be critical to driving adoption of new treatments.

The report is available on a limited-time pre-order discount

PRE-ORDER REPORT
Register Interest

About Alpharmaxim

Alpharmaxim was founded in 2001, helping cross-functional biopharma teams communicate effectively with clinicians about new medicines or alternative treatment regimes and their potential to improve the patient experience. With a significant focus on pre- and peri-launch work in speciality healthcare, Alpharmaxim has always had a strong awareness of the need to change behaviours and beliefs, and introduced the Belief Continuum® in 2007, with copyright granted in 2016. Alpharmaxim has consistently invested in behavioural science. We have established ARM BeSci Consulting – a specialist team within Alpharmaxim. Working with our academic partners, we have developed a proprietary model that practically evaluates and analyses behaviours and barriers to change. This model also identifies the proven and most effective behaviour change techniques to overcome these barriers. By adopting a behavioural science approach to communications planning, clients can expect targeted communications that achieve greater success, enabling more clarity and ensuring the right patients get the right medicine at the right time.
PRE-ORDER REPORT
visit main website

The report is for individual use and is Copyright Alpharmaxim Limited. All data in the report is owned by Alpharmaxim. Please contact us about multiple-copy discounts.

1. Cure Parkinson’s. Parkinson’s drug therapies in the clinical trial pipeline: 2023 update. https://cureparkinsons.org.uk/2023/06/parkinsons-clinical-trial-pipeline-2023/. Accessed 27 June 2024

Alpharmaxim logo in white